BridgeBio Pharma is teaming up with BlackDoctor and HealthyWomen to highlight how the heart condition ATTR-cardiac amyloidosis (ATTR-CM) is being “systematically missed in women.” The condition is a ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults. The American Heart Association's ...
In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...
Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM). It’s not only key to managing your care but also helps you determine whether others in ...
Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...
Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...
Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...
His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...
Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...
Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...
Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results